Tiyaboonchai, Amita http://orcid.org/0000-0002-0116-7393
Vonada, Anne
Posey, Jeffrey http://orcid.org/0000-0001-5205-8261
Pelz, Carl
Wakefield, Leslie http://orcid.org/0000-0001-5623-4285
Grompe, Markus http://orcid.org/0000-0002-6616-4345
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (1 F2 DK117516-01)
Article History
Received: 20 January 2022
Accepted: 15 November 2022
First Online: 30 November 2022
Competing interests
: The authors declare that Oregon Health and Science University, M.G., A.T., and A.V. have a financial interest in LogicBio Therapeutics, a company that may have a commercial interest in the results of this research and technology. M.G., A.T., and A.V. are inventors of technology that is utilized in this research, and that has been licensed to LogicBio Therapeutics. M.G. has significant financial interests in Yecuris Corp. and Ambys Medicines. A patent application on the APAP selection technology described herein has been filed by OHSU (Title: Methods of Gene Therapy. Filing number: PCT/US19/29890. M.G. and A.T. are coinventors). These potential conflicts of interest have been reviewed and managed by the Oregon Health and Science University. The remaining authors declare no competing interests.